LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 3, 2021--
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the following upcoming investor conferences:
The H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, on-demand beginning at 7:00 a.m. ET; and
The Cantor Virtual Global Healthcare Conference on September 30, 2021 at 3:20 p.m. ET.
Webcasts of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the conference webcasts will be available on Concert’s website for two weeks following the presentations.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210903005021/en/
Source: Concert Pharmaceuticals, Inc.